Big pharma and biotech take the earnings stage with reports from Eli Lilly and Novo Nordisk leading the lineup. Will they ...

The latest firm to top up its venture capital coffers is Austin, Texas-based Santé Ventures, which on Monday announced its ...

Reinforces Trinity Biotech’s growing position as a key player in diabetes care innovation– Senior commercial executives of Trinity Biotech are ...

Celebrate International Day of Women and Girls in Science 2026 by discovering some of the most influential women shaping ...

Krystal Biotech is engaged in developing genetic medicines. The biotech stock is near a buy point with earnings due soon.

For biotech companies the past two years have been challenging. Biotech investments have not reached the record levels of 2020 and 2021 and an anticipated stock recovery in 2024 failed to materialise.

The companies Aktis Oncology, Alumis, and Parabilis Medicines bagged the biggest biotech funding rounds overall in January ...

Immunology biotech Agomab Therapeutics is seeking to raise up to $212.5 million in its Nasdaq debut, joining a series of biotechs chipping away at 2025’s iced-over IPO market. | Immunology biotech ...

Eli Lilly will acquire Orna Therapeutics for up to $2.4 billion to gain access to the Watertown biotech's circular RNA ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Four drug companies — Agomab Therapeutics, Eikon Therapeutics, Spyglass Pharma, and Veradermics — went public this week, ...

When Neal Piper’s son, Noah, rang the bell at UVA Children’s Hospital in December 2020, it signaled the end of grueling chemotherapy treatments connected to beeping monitors and intravenous tubes.